NeuroSense Announces Third Quarter 2023 Financial Results an

Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial expected in early December 2023Patients who completed the 18-month PARADIGM trial, including the...

Related Keywords

Germany , Japan , Israel , Cambridge , Cambridgeshire , United Kingdom , , Prnewswire Neurosense Therapeutics Ltd , Company Phase , Drug Administration , Exchange Commission , Linkedin , European Medicines Agency Neurosense Opens Eu Office , Twitter , Nasdaq , European Medicines Agency , Neurosense Therapeutics Ltd , Sense Therapeutics , Amyotrophic Lateral Sclerosis , Completed Double Blind Segment , Investigator Initiated Trial , Slow Vital Capacity , Primec Ahead , Pivotal Phase , Sponsored Study Demonstrated Primec , Outstanding Effect , Ichida Stem Cell Lab , Southern California , Trial Under Preparation , First Patient Enrolled Expected , Valid Through , Neurosense Opens , Medium Sized Enterprise , Orphan Drug Designation , Neurosense Therapeutic , Annual Report , Neurosense Therapeutics , Interim Unaudited Statements , Markets ,